TrialSignal
Clinical trial intelligence report
A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01061099
Status
COMPLETED
Phase
PHASE1
Sponsor
Nationwide Children's Hospital
Executive brief
Investment-Ready Snapshot
This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01061099
Indication
Osteogenesis Imperfecta Type II
Modality
cell therapy
Target
Mesenchymal Stromal Cells
Intervention
Mesenchymal Stromal Cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.